Upgrade to FINVIZ*Elite to get real-time quotes, intraday charts, and advanced charting tools.

Last Close
Jun 17 04:00PM ET
4.33
Dollar change
-0.09
Percentage change
-1.93
%
Index- P/E- EPS (ttm)-1.58 Insider Own4.67% Shs Outstand15.21M Perf Week-6.48%
Market Cap65.86M Forward P/E- EPS next Y- Insider Trans0.00% Shs Float14.50M Perf Month8.52%
Income-13.05M PEG- EPS next Q- Inst Own1.59% Short Float0.88% Perf Quarter13.05%
Sales0.00M P/S- EPS this Y- Inst Trans-7.61% Short Ratio3.25 Perf Half Y101.40%
Book/sh0.54 P/B7.96 EPS next Y- ROA-120.38% Short Interest0.13M Perf Year134.05%
Cash/sh0.18 P/C23.44 EPS next 5Y- ROE-154.88% 52W Range1.00 - 5.87 Perf YTD30.82%
Dividend Est.- P/FCF- EPS past 5Y24.86% ROIC-269.12% 52W High-26.24% Beta0.75
Dividend TTM- Quick Ratio3.84 Sales past 5Y- Gross Margin- 52W Low332.57% ATR (14)0.26
Dividend Ex-Date- Current Ratio3.84 EPS Y/Y TTM20.25% Oper. Margin- RSI (14)48.94 Volatility1.87% 3.14%
Employees10 Debt/Eq0.01 Sales Y/Y TTM- Profit Margin- Recom1.00 Target Price12.00
Option/ShortNo / Yes LT Debt/Eq0.01 EPS Q/Q47.40% Payout- Rel Volume0.10 Prev Close4.41
Sales Surprise-97.00% EPS Surprise18.38% Sales Q/Q- EarningsFeb 28 BMO Avg Volume39.32K Price4.33
SMA20-3.57% SMA509.36% SMA20054.56% Trades Volume4,070 Change-1.93%
Date Action Analyst Rating Change Price Target Change
Feb-03-25Downgrade The Benchmark Company Speculative Buy → Hold
Dec-12-24Initiated Maxim Group Buy $8
May-12-25 07:35AM
May-07-25 08:16AM
May-05-25 07:35AM
Apr-30-25 07:35AM
Apr-28-25 07:35AM
07:35AM Loading…
Apr-10-25 07:35AM
Apr-03-25 07:35AM
Mar-27-25 07:25AM
Feb-10-25 07:25AM
Jan-30-25 07:35AM
Jan-24-25 07:35AM
Jan-10-25 07:35AM
Jan-09-25 07:25AM
Dec-04-24 07:35AM
Nov-19-24 07:25AM
07:35AM Loading…
Nov-12-24 07:35AM
Nov-06-24 07:35AM
Oct-31-24 07:35AM
Oct-14-24 07:35AM
Oct-11-24 07:35AM
Oct-02-24 07:35AM
Sep-30-24 07:35AM
Sep-23-24 07:35AM
Jul-31-24 07:35AM
Jul-24-24 07:35AM
Jul-18-24 11:01AM
Jul-17-24 07:35AM
Jun-12-24 07:22PM
May-29-24 07:21PM
May-08-24 07:25AM
07:25AM Loading…
Apr-30-24 07:25AM
Apr-29-24 07:25AM
Apr-17-24 07:25AM
Apr-10-24 07:25AM
Mar-26-24 10:25AM
Feb-20-24 10:25AM
Feb-06-24 07:25AM
Jan-29-24 07:24AM
Jan-22-24 07:25AM
Dec-21-23 12:30AM
Dec-04-23 04:35PM
02:15PM
07:25AM
Nov-27-23 07:25AM
Nov-16-23 07:25AM
Nov-08-23 07:25AM
Oct-30-23 07:25AM
Aug-31-23 07:25AM
Aug-23-23 07:25AM
Aug-22-23 07:25AM
Aug-15-23 07:25AM
Jul-31-23 07:52AM
Jul-26-23 07:25AM
Jun-21-23 07:25AM
May-30-23 07:25AM
May-19-23 07:25AM
May-10-23 07:25AM
07:25AM
Apr-26-23 07:25AM
Apr-04-23 07:25AM
Mar-16-23 07:25AM
Mar-14-23 07:25AM
Mar-08-23 07:25AM
Feb-16-23 04:44PM
Jan-31-23 07:25AM
Jan-30-23 07:25AM
Jan-25-23 07:25AM
Jan-20-23 09:40AM
Jan-09-23 10:25AM
Jan-06-23 07:25AM
Jan-03-23 10:25AM
Dec-29-22 10:25AM
Nov-07-22 10:25AM
Oct-28-22 07:25AM
Oct-26-22 07:25AM
Oct-13-22 10:25AM
Sep-26-22 07:25AM
Sep-20-22 07:25AM
Aug-25-22 07:25AM
Aug-08-22 04:00PM
Jul-22-22 07:25AM
Jul-06-22 11:00AM
Jun-24-22 08:35AM
Jun-23-22 11:00AM
Jun-21-22 04:21PM
08:35AM
Jun-20-22 07:05AM
Jun-02-22 08:00AM
May-31-22 08:27AM
Apr-27-22 07:40AM
Apr-06-22 09:34PM
Jan-28-22 11:02AM
07:08AM
Jan-27-22 07:45AM
Jan-06-22 07:30AM
Jan-05-22 07:45AM
Dec-14-21 07:25AM
Nov-22-21 07:50AM
Nov-09-21 07:30AM
Nov-05-21 02:57AM
Alterity Therapeutics Ltd. is a clinical stage biotechnology company. It engages in the business of research and development of therapeutic drugs designed to treat the underlying cause of degeneration of the brain focusing on Alzheimer's, Huntington, Parkinson's, and other neurological disorders. The company was founded by Geoffrey Paul Kempler on November 11, 1997 and is headquartered in Melbourne, Australia.